FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder

FDA DecisionapprovedLamliquePositive

AI Analysis

Summary

Azurity Pharmaceuticals, a privately held company, announced on September 29, 2026 that the FDA approved Lamlique (lamotrigine) oral suspension for seizures and bipolar disorder.

Outcome Details

FDA approved Lamlique (lamotrigine) oral suspension for seizures and bipolar disorder

Importance:5/10

Sentiment:

0.60

FDA approvallamotrigineoral suspensionepilepsybipolar disorderreformulationprivate company

Related Companies

$SHWZ $GBCMD $WHEN

Read the original article

Published by Drugs.com New Drug Approvals on September 29, 2026 7:09 PM

Read Original